Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dig into gut bugs to unlock constipation mystery

NCT ID NCT06801184

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study looks at the gut bacteria of 40 people with irritable bowel syndrome (IBS) who have constipation and produce high methane. Researchers will collect stool and blood samples to see which bacteria are present and how they change with standard treatment. The goal is to better understand the role of methane-producing microbes in IBS, which could lead to more targeted therapies in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward better diagnostic tools or treatments for constipation-predominant IBS with methane overgrowth.
What could go wrong
This is a small, early observational study with only 40 participants. It does not test a new treatment, so direct benefits are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with constipation-predominant irritable bowel syndrome who are methane producers suffering from constipation, attending the digestive functional explorations department for a prescribed breath test as part of an outpatient procedure or gut health workshop session.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient suffering from Irritable Bowel Syndrome (IBS) (abdominal pain for the past 6 months occurring on average at least 1 day per week in the last 3 months, with at least 2 of the following criteria: associated with defecation, associated with a change in stool frequency, associated with a change in stool consistency): 1. Predominant constipation type (IBS-C): Bristol Stool Scale 1-2 ≥ 25% of the time and Bristol Stool Scale 6-7 ≤ 25% of the time 2. Alternating diarrhea-constipation type (IBS-M): Bristol Stool Scale 1-2 25% of the time and Bristol Stool Scale 6-7 25% of the time 3. Unspecified type: absence of sufficient criteria to meet criteria for IBS-C, IBS-D, or IBS-M. * Patient exhibiting a high methane level (≥ 10 ppm) during a glucose breath test. * Aged ≥ 18 years at the time of study entry. * Patient not opposing participation in the study. Exclusion Criteria: * Patient who has been treated with antibiotics or probiotics in the last 3 months prior to inclusion. * Patient suffering from diarrhea-predominant IBS (Bristol Stool Scale 6-7 ≥ 25% of the time and Bristol Stool Scale 1-2 ≤ 25% of the time). * Patient with a history of abdominal surgery other than appendectomy and cholecystectomy. * Patient with a history of celiac disease. * Patient with proven inflammatory bowel disease. * Patient with a history of colorectal cancer. * Patient with uncontrolled hypothyroidism. * Patient with uncontrolled diabetes. * Pregnant or breastfeeding women. * Patient deprived of liberty by a judicial or administrative decision. * Adult patient under legal protection (guardianship, curators). * Patient unable to discontinue proton pump inhibitor treatment during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

constipation disorder irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Irritable bowel syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Edouard Herriot

    RECRUITING

    Lyon, 69007, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.